Brief: Matinas Biopharma Initiates EnACT Study Of MAT2203 For Treatment Of Fungal Cryptococcal Meningitis
14/10/2019 12:12
Oct 14 (Reuters) - Matinas BioPharma Holdings Inc MTNB.A :
* MATINAS BIOPHARMA INITIATES ENACT STUDY OF MAT2203 (ORAL
AMPHOTERICIN B) FOR THE TREATMENT OF FUNGAL CRYPTOCOCCAL
MENINGITIS
* MATINAS BIOPHARMA HOLDINGS INC - PLAN TO PROVIDE UPDATES
ON
ENACT LATER IN 2019 AND OVER COURSE OF 2020
Source text for Eikon: ID:nGNX6j8lVY
Further company coverage: MTNB.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Matinas BioPharma Holdings
See all newsBrief: Matinas Biopharma - May Offer Securities Up To $150 Million - SEC Filing
Brief: Matinas Biopharma Holdings Inc Keith Kucinski Resigns As CFO Effective January 17, 2026
Brief: Matinas Biopharma Holdings Inc - CFO Keith Kucinski Resigns Effective January 17, 2026 - SEC Filing
Brief: Matinas Biopharma Holdings Eric Ende Resigns As Chairman Of Matinas Biopharma
Brief: Matinas BioPharma Appoints Seasoned Biotech Leaders To Board Of Directors